← Back to Search

Ultrasound Device

Sofwave for Cellulite

N/A
Waitlist Available
Research Sponsored by Sofwave Medical LTD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post treatment follow-up visit.
Awards & highlights
No Placebo-Only Group

Summary

This trial uses the Sofwave System, a device that sends energy into the skin, to treat patients with skin issues on their upper thigh or buttocks. The Sofwave System has evolved to improve skin laxity and appearance.

Eligible Conditions
  • Cellulite

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post treatment follow-up visit.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post treatment follow-up visit. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of improvement in the appearance of cellulite on the upper thigh/buttock area

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: CelluliteExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sofwave
2020
Completed Phase 3
~240

Who is running the clinical trial?

Sofwave Medical LTDLead Sponsor
9 Previous Clinical Trials
503 Total Patients Enrolled
1 Trials studying Cellulite
60 Patients Enrolled for Cellulite

Media Library

Sofwave (Ultrasound Device) Clinical Trial Eligibility Overview. Trial Name: NCT05358847 — N/A
Cellulite Research Study Groups: Cellulite
Cellulite Clinical Trial 2023: Sofwave Highlights & Side Effects. Trial Name: NCT05358847 — N/A
Sofwave (Ultrasound Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05358847 — N/A
Cellulite Patient Testimony for trial: Trial Name: NCT05358847 — N/A
~17 spots leftby Dec 2025